



Vivimed

Date: 21.11.2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001
Scrip Code: **532660**

National Stock Exchange of India Limited
Exchange Plaza, Sandra Kurla Complex,
Bandra (E), Mumbai - 400 051
Symbol: **VIVIMEDLAB**

Dear Sir/ Madam,

Sub: Disclosure of Related Party Transactions for the Half Year Ended 30.09.2022

Ref. Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 ("Listing Regulations")

In compliance with the above referred Listing Regulations, please find enclosed herewith Related Party Transactions on a consolidated basis for the half year ended 30.09.2022.

Note that the financial results have been approved by the Board of Directors on 14.11.2022

Please take the same on record.

Thank you,
For Vivimed Labs Limited


Santosh Varalwar
Managing Director



Encl: As above

Vivimed Labs Limited.

CIN: L02411KA1988PLC009465

Registered Office: #78/A, Kolhar Industrial Area,
Bidar, Karnataka - 585 403, India.

T +91 (0) 8482-232045, F +91 (0) 8482-232436

Email: contact@vivimedlabs.com | www.vivimedlabs.com

Corporate Office:

North End, Road No. 2
Banjara Hills, Hyderabad,
Telangana - 500 034, India.

GSTIN: 36AAACV6060A1ZQ

T +91(0) 40-6608-6608, F +91(0) 40-6608-6699



Vivimed

Vivimed Labs Limited

Related Party Disclosures for the half year ended September 30, 2022

	Key Management Personnel	Name	Nature of relationship/ Designation
		1	Mr. Santosh Varalwar
	Dr. Manohar Rao Varalwar	Whole Time Director	
	Mr. Subhash Varalwar	Non-Executive non – Independent Director	
	Mr. Sandeep Varalwar	Whole Time Director	
	Dr. Jamalapuram Harigopal	Independent Director	
	Ms. Aparna Bidarkar	Independent Director	
	Mr. Ramakanta Tripathy	Chief Financial Officer - Appointed w.e.f. 12.04.2022	
	Mr. Yugandhar Kopparthi	Company Secretary & Compliance Officer	

Consolidated disclosure of related party transactions for the half year ended September 30, 2022

Sl.No	Nature of Transaction	(Rs. In Millions)
1	Payment to Key Managerial personnel and Directors (This amount does not include the sitting fees paid to Non-Executive Directors)	18.34

Related Party Transactions for the half year ended September 30, 2022

SI No	Party Name	Nature of Transaction	During April - Sept 2022
			Debit /(Credit) (Rs. In Millions)
1	Finoso Pharma Private Limited (100% Wholly owned Subsidiary)	Purchase of goods and services	(2.86)

For Vivimed Labs Limited

Santosh Varalwar
Managing Director

